Leader in the development of permanent seed brachytherapy in the treatment of cancer.
Physicians Clinicians
- Scientific Articles
- Cesium-131 Data
- Treatment Centers
- Physician Interviews
- Participating Centers
- Physician Information Form
- Release Criteria (PDF)
History of IsoRay - Prostate Cancer Brachytherapy Isotope
Cesium-131 combines the best physical characteristics of other currently used radioisotopes, a higher energy level than Iodine-125 and a shorter half-life than Palladium-103. The potential clinical benefits of treating your prostate brachytherapy patients with a high energy, short half-life isotope are many and Cesium-131 has the advantage of a higher initial dose rate while using significantly less total dose (115 Gy vs 145 Gy) than I-125. These isotope characteristics translate to a biological life of approximately one month for Cesium-131 versus two months for Palladium-103, and eight months for Iodine-125. The rapid delivery of radiation translates to a lower prescribed dose to create the same biologic effect; specifically, 115 Gy for Cesium-131, 125 Gy for Palladium-103 and 145 Gy for Iodine-125.
Isotope Dose Delivery¹
To read articles and studies on Cesium-131 and related brachytherapy topics, click here. For more information, please contact IsoRay Medical.
- Chen, Z., Dose rate constant of a Cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry: Medical Physics. 32 (11), November 2005.